California Public Employees Retirement System Decreases Holdings in Pfizer Inc. $PFE

California Public Employees Retirement System trimmed its position in Pfizer Inc. (NYSE:PFE) by 22.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 10,840,185 shares of the biopharmaceutical company’s stock after selling 3,133,806 shares during the quarter. California Public Employees Retirement System’s holdings in Pfizer were worth $304,392,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Clifford Swan Investment Counsel LLC boosted its stake in shares of Pfizer by 0.8% in the first quarter. Clifford Swan Investment Counsel LLC now owns 489,295 shares of the biopharmaceutical company’s stock worth $13,739,000 after acquiring an additional 3,745 shares during the last quarter. Bartlett & CO. Wealth Management LLC raised its stake in Pfizer by 2.4% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 100,995 shares of the biopharmaceutical company’s stock valued at $2,656,000 after purchasing an additional 2,325 shares during the last quarter. Ranch Capital Advisors Inc. raised its stake in Pfizer by 5.4% in the 1st quarter. Ranch Capital Advisors Inc. now owns 77,996 shares of the biopharmaceutical company’s stock valued at $2,190,000 after purchasing an additional 3,966 shares during the last quarter. Heartland Bank & Trust Co purchased a new position in Pfizer in the 1st quarter valued at $616,000. Finally, John G Ullman & Associates Inc. lifted its holdings in Pfizer by 3.9% in the 1st quarter. John G Ullman & Associates Inc. now owns 214,087 shares of the biopharmaceutical company’s stock valued at $6,012,000 after purchasing an additional 8,022 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PFE. Morgan Stanley upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. HSBC lowered shares of Pfizer from a “buy” rating to a “hold” rating and lowered their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. UBS Group reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. Finally, Bank of America decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Stock Down 0.2%

NYSE PFE opened at $25.08 on Friday. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The business’s fifty day simple moving average is $25.21 and its 200-day simple moving average is $26.17. The firm has a market cap of $142.94 billion, a PE ratio of 19.15 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the previous year, the company posted $0.92 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent commentary continues to focus on Pfizer’s pipeline potential, with articles asking whether the company can strengthen its growth story through new drug development and recent approvals, which could support a longer-term rebound. Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story?
• Positive Sentiment: Pfizer remains attractive to income-focused investors, with coverage highlighting it as a high-yield dividend stock and a potential “buy on the dip” name, which may help limit downside. 3 High-Yield Dividend Stocks to Buy and Hold
• Neutral Sentiment: Analysts are still modeling solid full-year earnings, but Erste Group slightly trimmed its FY2026 EPS estimate for Pfizer to $2.92 from $2.95, signaling only a small downward revision versus the consensus of $2.96.
• Neutral Sentiment: Another valuation-focused note said Pfizer looks “fairly priced” given mixed pipeline risks, suggesting the stock may not be obviously cheap despite its lower valuation and high dividend.
• Negative Sentiment: Pfizer suspended sales of Premarin vaginal cream in India because of supply challenges, adding another operational headwind for the company. Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
• Negative Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines, keeping legal risk and potential costs in focus for PFE. Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech…

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.